Company intelligence / Profile preview

Access Vaccines

Bradenton, Florida, United States

Ownership: Private
Development stage: Other

Overview

Access Vaccines is a biopharmaceutical company dedicated to the development and commercialization of vaccines for infectious diseases. The company focuses on identifying high-value vaccine candidates and leveraging strategic partnerships to navigate the clinical trial and regulatory approval processes. Their lead asset, AV-001, is a recombinant protein vaccine candidate designed to prevent shingles (herpes zoster) in adults. Access Vaccines aims to improve global health by providing more accessible and cost-effective immunization options. The company operates with a lean business model, focusing on asset development and strategic licensing.

Therapeutic areas: Infectious Diseases
Modalities: VaccineRecombinant protein
Industry: Biotech

Partnerships

Barinthus BiotherapeuticsEurocine Vaccines

Beyond the preview

Go deeper on Access Vaccines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Access Vaccines.

Explore the full profile